Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Brigatinib (Alunbrig) in ALK-positive non?small-cell lungcancer (NSCLC). Oncology Fact Sheet Nr. 4. Brigatinib (Alunbrig®) in ALK-positive non–small-cell lungcancer (NSCLC) - Repository of AIHTA GmbH English | Browse - - - Brigatinib (Alunbrig®) in ALK-positive non–small-cell lungcancer (NSCLC) Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lungcancer (NSCLC). Oncology Fact Sheet Nr. 4. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z
Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) Research, University College London, London, UK 5 Research Department of Primary Care and Population Health, and Priment Clinical Trials Unit, University College London, London, UK 6 Cancer Research UK & UCL Cancer Trials Centre, University College London, London, UK 7 UCL Cancer Institute, University College London, London, UK 8 Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK 9 Lungs for Living Research Centre, UCL Respiratory
Hand-held Fan Airflow Stimulation Relieves Dyspnea in LungCancer Patients. The main symptom of lungcancer is dyspnea which can lead to depression, anxiety, limited independent activities, and decreased quality of life. The purpose of this study was to identify the effect of airflow stimulation from a hand-held fan as nonpharmacological palliative intervention on dyspnea in patients with lung cancer.This study used open, randomized, controlled, crossover trial design involved 21 participants (...) . Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenced dyspnea scale (P = 0.003) and respiratory rate (RR) (P = 0.008). Combination of airflow stimulation and diaphragmatic breathing can lower both dyspnea scale and RR significantly (P < 0.0001).This combination can be applied on nonhypoxemic dyspneic lungcancer patients.
Cost-Effectiveness Analysis of LungCancer Screening in the United States: A Comparative Modeling Study. Recommendations vary regarding the maximum age at which to stop lungcancer screening: 80 years according to the U.S. Preventive Services Task Force (USPSTF), 77 years according to the Centers for Medicare & Medicaid Services (CMS), and 74 years according to the National Lung Screening Trial (NLST).To compare the cost-effectiveness of different stopping ages for lungcancer screening.By (...) using shared inputs for smoking behavior, costs, and quality of life, 4 independently developed microsimulation models evaluated the health and cost outcomes of annual lungcancer screening with low-dose computed tomography (LDCT).The NLST; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SEER (Surveillance, Epidemiology, and End Results) program; Nurses' Health Study and Health Professionals Follow-up Study; and U.S. Smoking History Generator.Current, former, and never-smokers aged
Bevacizumab (Zirabev) - colorectal cancer, non-small cell lungcancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity
Thoren ? Volker Vervölgyi Keywords: dacomitinib, carcinoma – non-small-cell lung, benefit assessment, NCT01774721 Extract of dossier assessment A19-39 Version 1.0 Dacomitinib (non-small cell lungcancer) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 8 2.3 Research question 1: patients with the activating EGFR (...) It was assumed for the present therapeutic indication that the NSCLC patients have stage IIIB to IV disease (staging according to the International Association for the Study of LungCancer [IASLC], Union for International Cancer Control [UICC]), without medical indication for curative resection, radiotherapy or radiochemotherapy. In the present assessment, the following terms are used for the respective populations of the research questions: ? Research question 1: patients with the activating EGFR mutations
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy
Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lungcancer (NSCLC) Published 09 December 2019 1 Statement of advice SMC2254 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation atezolizumab (Tecentriq®) is not recommended for use within NHSScotland. Indication under review: In combination with nab-paclitaxel and carboplatin for the first (...) -line treatment of adult patients with metastatic non-squamous non-small cell lungcancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium
. Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lungcancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell).1568 participants were (...) randomised during 2007-2011 from 10 UK centres. 85.2% of those screened provided an adequate baseline sputum sample. There were 42 lungcancers among 785 screened individuals and 36 lungcancers among 783 controls. 54.8% (23 out of 42) of screened individuals versus 45.2% (14 out of 31) of controls with known staging were diagnosed with early-stage disease (one-sided p=0.24). Relative risk was 1.21 (95% CI 0.75-1.95) or 0.82 (95% CI 0.52-1.31) for early-stage or advanced cancers, respectively. Overall
Life-Gained-Based Versus Risk-Based Selection of Smokers for LungCancer Screening. Although risk-based selection of ever-smokers for screening could prevent more lungcancer deaths than screening according to the U.S. Preventive Services Task Force (USPSTF) guidelines, it preferentially selects older ever-smokers with shorter life expectancies due to comorbidities.To compare selection of ever-smokers for screening based on gains in life expectancy versus lungcancer risk.Cohort analyses (...) and model-based projections.U.S. population of ever-smokers aged 40 to 84 years.130 964 National Health Interview Survey participants, representing about 60 million U.S. ever-smokers during 1997 to 2015.Annual computed tomography (CT) screening for 3 years versus no screening.Estimated number of lungcancer deaths averted and life-years gained after development of a mortality model.Using the calibrated and validated mortality model in U.S. ever-smokers aged 40 to 84 years and selecting 8.3 million ever
Atezolizumab (Tecentriq) - non-squamous non-small cell lungcancer (NSCLC) 1 Published 11 November 2019 1 SMC2208 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under (...) the end of life medicine process: atezolizumab (Tecentriq ® ) is not recommended for use within NHSScotland. Indication under review: In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lungcancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin
Dacomitinib (Vizimpro) - non-small cell lungcancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lungcancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Most patients with small-cell lungcancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination (...) with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC.This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum
Lorlatinib (Lorbrena) for Non-Small Cell LungCancer — Details Lorlatinib (Lorbrena) for Non-Small Cell LungCancer — Details | CADTH.ca Find the information you need Lorlatinib (Lorbrena) for Non-Small Cell LungCancer — Details Lorlatinib (Lorbrena) for Non-Small Cell LungCancer — Details Project Number pCODR 10183 Brand Name Lorbrena Generic Name Lorlatinib Tumour Type Lung Indication Non-Small Cell LungCancer (NSCLC) Funding Request For the treatment of adult patients with anaplastic (...) lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib. Review Status Under Review Pre Noc Submission No NOC Date Manufacturer Pfizer Canada ULC Sponsor Pfizer Canada ULC Submission Date June 11, 2019 Submission Deemed Complete June 25, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ June 25, 2019 Check-point meeting
Tecentriq for Small Cell LungCancer – Details Tecentriq for Small Cell LungCancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell LungCancer – Details Tecentriq for Small Cell LungCancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell LungCancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lungcancer (ES-SCLC
Entrectinib (Rozlytrek) - metastatic non-small cell lungcancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review
Mvasi for Metastatic Colorectal Cancer / Non-Small Cell LungCancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell LungCancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell LungCancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell LungCancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell LungCancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lungcancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre
Tagrisso for Non-Small Cell LungCancer (first line) – Details Tagrisso for Non-Small Cell LungCancer (first line) – Details | CADTH.ca Find the information you need Tagrisso for Non-Small Cell LungCancer (first line) – Details Tagrisso for Non-Small Cell LungCancer (first line) – Details Project Number pCODR 10137 Brand Name Tagrisso Generic Name Osimertinib Strength 40 mg and 80 mg Tumour Type Lung Indication Non-Small Cell LungCancer (first line) Funding Request For the first-line (...) treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date July 10, 2018 Manufacturer AstraZeneca Canada Inc. Sponsor AstraZeneca Canada Inc. Submission Date May 16, 2018 Submission Deemed Complete May 24, 2018 Submission Type New Indication Prioritization Requested Requested and Not Granted Stakeholder Input Deadline ‡ May